10-K · February 26, 2026
Cytek reported fiscal 2025 revenue of $201.5 million (up $1.0 million vs. $200.5 million in 2024) while recording a materially larger GAAP net loss of $66.5 million in 2025 (vs. $6.0 million in 2024). The company…
Earnings analysis · 10-Q
CTKB earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% increase year-over-year, but missed analyst expectations. The net loss more than doubled to $18.9 million, driven by higher operating expenses.…
Read full summary
Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% increase year-over-year, but missed analyst expectations. The net loss more than doubled to $18.9 million, driven by higher operating expenses. Management reaffirmed its 2026 revenue guidance of $205 million to $212 million, targeting 2-5% growth for the year. The company faced an increase in general and administrative costs due to litigation and consulting expenses.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.15
- Segment
- Direct Sales: $30.3M; Distributor Sales: $13.9M
What stood out
-
Revenue Growth Year-Over-Year
Q1 2026 revenue increased 6% to $44.1M from $41.5M in Q1 2025.
-
Increased Service Revenue
Service revenue for Q1 2026 rose 15% to $15.4M, up from $13.3M in Q1 2025.
-
Strong Cash Position
Cash and cash equivalents at $262.2M as of March 31, 2026, slightly up from $261.5M at year-end 2025.
-
Reaffirmed 2026 Revenue Guidance
Management confirmed 2026 revenue guidance of $205M to $212M, expecting 2-5% growth.
-
Operating Expense Control Efforts
Despite a $5.6M increase in general and administrative expenses, the company is focusing on cost management.
-
Increased Interest Income
Interest income rose 55% to $787,000 in Q1 2026 from $508,000 in Q1 2025.
What to watch
-
Continued Net Loss
Net loss widened to $18.9M in Q1 2026 from $11.4M in Q1 2025, indicating rising operational pressures.
-
High General Administrative Costs
General and administrative expenses surged 43% to $18.5M due to litigation and consulting.
-
Potential Delisting from Nasdaq
Failure to comply with Nasdaq continued listing requirements could jeopardize the trading of the stock.
Management's outlook
2026 revenue guidance reaffirmed; growth of 2% to 5% expected.
Earlier filings 4
10-Q · November 5, 2025
Cytek reported quarterly revenue of $52.293M (three months ended Sept. 30, 2025) — up $0.793M (+1.5%) year-over-year from $51.500M — driven by service revenue growth but with product sales slightly down. Gross profit…
10-Q · May 8, 2025
Cytek reported Q1 revenue of $41,457,000, down from $44,860,000 a year ago, with gross profit of $20,157,000 (48.6%) and an operating loss of $14,975,000. Net loss widened to $11,402,000 (EPS $(0.09)) versus $6,169,000…
10-Q · November 7, 2024
Cytek reported Q3 revenue of $51.5M (up $3.5M or 7.3% vs. $48.0M a year ago) and turned a year-ago loss into net income of $0.9M (EPS $0.01 vs. $(0.05)). Gross profit was $29.0M (56.3% margin) while operating loss…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.